002880 Shen Zhen Weiguang Biological Products
- 29.77
- -0.33-1.10%
Shen Zhen Weiguang Biological Products News
Weiguang Biological Products Gets Nod for Human Prothrombin Complex
Shenzhen Weiguang Biological Products (SHE:002880) received a drug registration certificate from China's National Medical Products Administration for its human prothrombin complex, according to a Frid
Weiguang Biotech (002880.SZ): Received the “Drug Registration Certificate” for human prothrombin complex
Gelonghui, May 31 | Weiguang Biotech (002880.SZ) announced that it has recently received the approval and issuance of the “Drug Registration Certificate” for the human prothrombin complex from the State Drug Administration. Clinically, it is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiencies (alone or in combination).
Weiguang Biology (002880.SZ): The main business is blood products. It is a bioactive preparation prepared from healthy human plasma using biological processes or separation and purification technology
Gelonghui, May 24 | Weiguang Biology (002880.SZ) said on the investor interactive platform that the company's main business is blood products, which are bioactive preparations prepared using biological processes or separation and purification techniques using healthy human plasma as raw materials. Weiguang Life Science Park focuses on synthetic biology, brain science, etc., to build a core technology platform for genes, macromolecules, and cells, and is committed to building a biomedical specialty park characterized by innovation incubation and transformation of results.
Weiguang Biotech (002880.SZ): Net profit of 468.319 million yuan in the first quarter increased 2.40% year-on-year
Gelonghui, April 25 | Weiguang Biotech (002880.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 226 million yuan, up 8.53% year on year; net profit attributable to shareholders of listed companies was 468.319 million yuan, up 2.40% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 455.227 million yuan, up 1.23% year on year; basic earnings per share were 0.2065 yuan.
Earnings Growth of 0.8% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Shenzhen Weiguang Biological Products (SZSE:002880) Shareholders
You can invest in an index fund if you want to make sure your returns approximately match the overall market. In contrast individual stocks will provide a wide range of possible returns, and may fall
Some Shareholders Feeling Restless Over Shenzhen Weiguang Biological Products Co., Ltd.'s (SZSE:002880) P/E Ratio
There wouldn't be many who think Shenzhen Weiguang Biological Products Co., Ltd.'s (SZSE:002880) price-to-earnings (or "P/E") ratio of 30.7x is worth a mention when the median P/E in China is similar
Weiguang Biology (002880.SZ): The company successfully carried out pulping work in 2023, with an annual pulping volume of about 517 tons
Gelonghui, January 22丨Weiguang Biotech (002880.SZ) said on the investor interactive platform that the company's pulping work in 2023 was carried out smoothly, with an annual pulping volume of about 517 tons.
Weiguang Biotech (002880.SZ): 2023 net profit pre-increased 69%-111%
Gelonghui, January 19 | Weiguang Biotech (002880.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 199 million yuan to 248 million yuan, an increase of 69%-111% over the same period of the previous year; net profit after deducting non-recurring profit and loss was 171 million yuan to 213 million yuan, an increase of 69%-111% over the same period last year; basic earnings per share were 0.88 yuan/share - 1.10 yuan/share. During the reporting period, the overall demand for blood products was good, the company had sufficient orders for related blood products, and actual operating income and net profit
Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
With its stock down 14% over the past month, it is easy to disregard Shenzhen Weiguang Biological Products (SZSE:002880). But if you pay close attention, you might find that its key financial indica
Weiguang Biotech (002880.SZ): Currently no gene editing therapy is being developed
On December 28, Gelonghui Biotech (002880.SZ) said on the investor interactive platform that the company is currently not developing gene editing therapy.
A Look At The Intrinsic Value Of Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shenzhen Weiguang Biological Products fair value estimate is CN¥31.18 Current share price of CN¥36.19 suggests Shenzhen Weiguang Biological P
Weiguang Biotech (002880.SZ)'s approval for non-public stock issuance expires
Weiguang Biotech (002880.SZ) issued an announcement. The company received an announcement from the China Securities Regulatory Commission in November 2022...
Everbright Securities: The expansion of both supply and demand in the blood products industry is expected to usher in a golden period of development
As the supply capacity of raw plasma continues to increase, product sales in the blood products industry are expected to benefit from increased demand and ushered in a golden period of development.
Weiguang Biological Products Gets Registration Certificate for Human Coagulation Factor VIII Drug
Shenzhen Weiguang Biological Products (SHE:002880) obtained a drug registration certificate from China's National Medical Products Administration for its drug, human coagulation factor VIII. The drug,
Weiguang Biotech (002880.SZ) obtained a drug registration certificate relating to human coagulation factor VIII
Weiguang Biotech (002880.SZ) issued an announcement. The company has recently been approved and issued by the State Drug Administration...
Concerns Surrounding Shenzhen Weiguang Biological Products' (SZSE:002880) Performance
Following the solid earnings report from Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880), the market responded by bidding up the stock price. However, we think that shareholders should
[BT Financial Report Instantaneous Analysis] Weiguang Biotech's 2023 Quarterly Report: Operating income increased by 78.75%, net profit increased by 107.83%, and net operating cash flow increased dramatically
This financial report was announced at 18:12:51 2023-10-25 at 18:12:51. Shenzhen Weiguang Biological Products Co., Ltd. (stock code: 002880) is one of the earliest domestic enterprises engaged in the production and operation of blood products, and one of the first to pass the national GMP certification. The company's main products include human albumin, immunoglobulins, and coagulation factors, etc., with a total of 21 specifications. The company has reached cooperation agreements with Belarusian government agencies on production licenses and technology transfer services for human blood albumin and intravenous human immunoglobulin (pH4), becoming the first in China to achieve blood product technology
Weiguang Biotech (002880.SZ) released results for the first three quarters, with net profit of 151 million yuan, an increase of 107.83% over the previous year
Weiguang Biotech (002880.SZ) released its report for the first three quarters of 2023, with revenue of 735 million yuan, the same...
Weiguang Biotech (002880.SZ) distributes 2 yuan per 10 shares for the semi-annual share registration date is October 30
Weiguang Biotech (002880.SZ) announced that the company will implement the distribution of benefits for the semi-annual period of 2023, every 10...
Shenzhen Weiguang Biological Products' (SZSE:002880) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
While Shenzhen Weiguang Biological Products Co., Ltd. (SZSE:002880) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 12% in
Analysis
Price Target
No Data
